Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
American Innovation in Genetic Testing is Redefining Cancer Treatment
WASHINGTON, Nov. 16, 2011 /PRNewswire-USNewswire/ --
Watch it live: Thursday at 8:15 a.m.
American innovation in genetic testing is redefining cancer treatment, and the pace of discovery promises new cancer-fighting therapies across a range of cancer types and conditions. That will be among the topics of discussion today at The Hill's policy briefing, "The Innovation Revolution: Genetic Testing in Today's Cancer Care."
The briefing will take place from 8:30 a.m. to 10 a.m. in Room 1539 Longworth House Office Building.
Featured speakers include Representatives Michael Burgess, MD, (R-TX) and Charles Gonzalez (D-TX). Rep. Burgess, a physician himself, serves as vice chair of the House Energy and Commerce Health Subcommittee, and Rep. Gonzalez also is a member of the House Energy and Commerce Health Subcommittee
The Hill's policy briefing, sponsored by the American Clinical Laboratory Association and Results for Life, also features comments by Mara Bloom, Executive Director of Massachusetts General Hospital Cancer Center, and Marc Grodman, MD, Chairman, President and CEO of Bio-Reference Laboratories, on how new genetic tests are being translated into life-saving care for patients. Joining the discussion on genetic testing's influence on recommended clinical treatment guidelines is Bill McGivney, PhD, CEO of the National Comprehensive Cancer Network.
Battelle Memorial Institute Senior Director Simon Tripp will paint a vision of the future of genetic testing and its impact on medical care, job growth, and the economy.
The American Clinical Laboratory Association represents the nation's clinical laboratories. The group's educational campaign, Results for Life, focuses on the value of laboratory medicine. See www.labresultsforlife.org
SOURCE American Clinical Laboratory Association